# PA NT COOPERATION TREAT

From the INTERNATIONAL BUREAU

## PCT

### NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

| | |
|---|---|
| **Date of mailing** (day/month/year)<br>12 October 2000 (12.10.00) | |
| **International application No.**<br>PCT/EP00/01458 | **Applicant's or agent's file reference**<br>SCB 534 PCT |
| **International filing date** (day/month/year)<br>23 February 2000 (23.02.00) | **Priority date** (day/month/year)<br>26 February 1999 (26.02.99) |
| **Applicant**<br>PROTTI, Maria, Pia et al | |

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:

15 September 2000 (15.09.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

| | |
|---|---|
| **The International Bureau of WIPO**<br>**34, chemin des Colombettes**<br>**1211 Geneva 20, Switzerland** | Authorized officer<br>Pascal Piriou |
| Facsimile No.: (41-22) 740.14.35 | Telephone No.: (41-22) 338.83.38 |

14

TENT COOPERATION TR Y

REC'D 16 JUL 2001
WIPO PCT

# PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| Applicant's or agent's file reference | FOR FURTHER ACTION | See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) |
|---|---|---|
| SCB 534 PCT | | |
| International application No. | International filing date *(day/month/year)* | Priority date *(day/month/year)* |
| PCT/EP00/01458 | 23/02/2000 | 26/02/1999 |
| International Patent Classification (IPC) or national classification and IPC<br>C07K14/47 | | |
| Applicant<br>FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR | | |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

   ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

| Date of submission of the demand | Date of completion of this report |
|---|---|
| 15/09/2000 | 12.07.2001 |
| Name and mailing address of the international preliminary examining authority:<br>European Patent Office<br>D-80298 Munich<br>Tel. +49 89 2399 - 0 Tx: 523656 epmu d<br>Fax: +49 89 2399 - 4465 | Authorized officer<br>Vix, O<br>Telephone No. +49 89 2399 7326 |

Form PCT/IPEA/409 (cover sheet) (January 1994)

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/01458

## I. Basis f th r p rt

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
**Description, pages:**

1-17 as originally filed

**Claims, No.:**

1-9 as originally filed

**Drawings, sheets:**

1/3-3/3 as originally filed

**Sequence listing part of the description, pages:**

1-3, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

   *(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

   ☐ the entire international application.

   ☒ claims Nos. 6-7.

because:

   ☒ the said international application, or the said claims Nos. 6-7 relate to the following subject matter which does not require an international preliminary examination (*specify*):
   **see separate sheet**

   ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

   ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

   ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

   ☐ the written form has not been furnished or does not comply with the standard.

   ☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

| | | | |
|---|---|---|---|
| Novelty (N) | Yes: | Claims | 1-9 |
| | No: | Claims | |
| Inventive step (IS) | Yes: | Claims | |
| | No: | Claims | 1-9 |
| Industrial applicability (IA) | Yes: | Claims | 1-5,8-9 |
| | No: | Claims | |

2. Citations and explanations
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
**see separate sheet**

**Re It m III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Industrial applicability (Art. 33(4) PCT)

For the assessment of the present claims 6-7 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. Consequently, under the provision of Rule 67.1(iv) PCT, no statement with regard to industrial applicability of said claims will be made (Article 34(4)(a)(i) PCT).

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following documents:

D1: WO 99 14326 A (STROOBANT VINCENT ;HEIRMAN CARLO (BE); CHAUX PASCAL (BE); CORTHALS) 25 March 1999 (1999-03-25)

D2: CHAUX P ET AL: 'IDENTIFICATION OF MAGE-3 EPITOPES PRESENTED BY HLA-DR MOLECULES TO CD4+ T LYMPHOCYTES' JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO1, vol. 189, no. 5, 1 March 1999 (1999-03-01), pages 767-777, ISSN: 0022-1007

D3: WO 95 19783 A (CELIS ESTEBAN ;GREY HOWARD M (US); CYTEL CORP (US); KUBO RALPH T () 27 July 1995 (1995-07-27)

D4: WO 95 19783 A (CELIS ESTEBAN ;GREY HOWARD M (US); CYTEL CORP (US); KUBO RALPH T () 27 July 1995 (1995-07-27)

1. Novelty (Art. 33(2) PCT)

The opinion has been established under the assumption of valid priority rights. Should this however not be the case, the document D2 and D3 cited in the ISR as P-document might become important.

The present application deals with 15 residues long peptides which are binding MHC class II molecules.
Only shorter MAGE-3 peptides have been described in D3 and D4 (peptides up to 10 or eleven residues long). The peptides in D3 and D4 elicit an immune response via their binding to MHC class I molecules.
Thus, this peptide selection appears to be novel over the available prior art.

2. Inventive step (Art. 33(3) PCT)

The application relates to peptides derived from the protein MAGE-3, pharmaceuticals compositions containing them and the use thereof for inducing an immune response against tumors.

D3 deals with peptides based on epitopes derived from the product of the tumor associated gene MAGE-3. Compared to the present application, the peptides in D3 are only 9-residue epitopes of MAGE-3, but these peptides appear to induce CTL response that kill melanoma and other tumor cell lines.
The problem to be solved by the present invention may therefore be regarded as the provision of alternative peptides derived from MAGE-3 and capable of inducing an immune response against tumors.

From the table 3 in D3 (page 35), it appears that the 9-residues epitope EVDPIGHLY derived from MAGE-3 is the highest MHC binder. This peptide is able to elicit CTL in one of the blood donor in D3 (page 33, line 1-14).
Part of the typical signature of the D3 peptide is found in the peptide of claim 1 (EVDPIGHL for peptide (f) and PIGHLY for the peptide (g)).
The same observation can be made in D4. An 11 residues and 10 residues peptide derived from MAGE3 (D4, Table 12) are comprised in two sequences of claim 1. The D4 peptide (MAGE3[$11_{195}$]) is contained in the sequence of claim 1h) and the D4 peptide (MAGE3[$10_{112}$]) is contained in the sequence of claim 1 b).

Thus, it appears from D3 and D4 that several portions of MAGE-3 were clearly identified as potential epitopes for inducing an immune response against tumor. The size difference between the peptides binding to class I or II molecules is known. The

man skilled in the art willing to solve the technical problem could choose a range of longer peptides (such as 15 residues long, in order to target MHC class II molecules) comprising the portions of MAGE-3 already identified in D3 or D4 as eliciting an immune response against tumor. The choice and testing of longer MAGE-3 peptides (15 residues in the present case) compatible with MHC class II binding, compared to the 4, 5 or 6 residues shorter peptides described in the prior art D3 and D4 does not appear to involve an inventive step. The compositions comprising peptides and their use for the preparation of medicaments or vaccine are routine methods in the field. Therefore, in absence of evidence showing unknown or unexpected effects or properties of presently claimed peptides, the presence of an inventive step cannot be acknowledged. Consequently, the subject-matter of claims 1-9 does not satisfy the criterion set forth in Article 33(3) PCT.

**Re Item VIII**

**Certain observations on the international application**

1. The composition of claim 4 is "further comprising one or more peptides binding MHC class I molecules". Due to the broad range of the MHC class I binding peptides such a definition might be unclear or open to interpretation. If this technical feature is essential to elicit an effective immune response, the choice of these additional peptides should be clearly defined to avoid any undue burden to the skilled person willing to perform the invention.

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07K 14/47, A61K 38/17, A61P 35/00 | A2

(11) International Publication Number: **WO 00/52045**

(43) International Publication Date: 8 September 2000 (08.09.00)

(21) International Application Number: PCT/EP00/01458

(22) International Filing Date: 23 February 2000 (23.02.00)

(30) Priority Data:
MI99A000396 26 February 1999 (26.02.99) IT

(71) Applicant *(for all designated States except US)*: FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR [IT/IT]; Via Olgettina, 60, I–20132 Milano (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: PROTTI, Maria, Pia [IT/IT]; Via Olgettina, 60, I–20132 Milano (IT). DELLABONA, Paolo [IT/IT]; Via Olgettina, 60, I–20132 Milano (IT).

(74) Agents: MINOJA, Fabrizio et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I–20122 Milano (IT).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*Without international search report and to be republished upon receipt of that report.*

(54) Title: MAGE–3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF CLASS II AND THE USE THEREOF

(57) Abstract

Peptides derived from the protein MAGE–3, pharmaceutical compositions containing them and the use thereof for inducing an immune response against tumors.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

# MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF CLASS II AND THE USE THEREOF

The present invention relates to peptides derived from MAGE-3 protein and to the use thereof as immunostimulants, specifically as agents capable of stimulating the $CD4^+$ T cell immune response.

The importance of $CD4^+$ T lymphocytes in anti-tumor immunity has been clearly demonstrated in animal models. $CD4^+$ T cells exert helper activity for the induction and maintenance of anti-tumor $CD8^+$ T cells (Greenberg, P.D., 1991,. Adv. Immunol. 49:281-355; Chen, P., et al., 1993, J. Immunol. 151:244-255; Mandelboim, O., et al., 1995,. Nat. Med. 1:1179-1183; Mayordomo, J.I., et al., 1995, Nat. Med. 1:1297-1302; Bellone, M., et al., 1997,. J. Immunol. 158:783-789; Ostrand-Rosemberg, S., et al., 1990, J. Immunol. 144:4068-4071; James, R., et al., 1991, Immunology 72:213-218), but they may also have an effector function either by indirect mechanism against MHC class II negative tumors, via macrophages activation, or by direct mechanism against MHC class II positive tumors.

Recently, the requirement of cognate $CD4^+$ T cell help for optimal induction of anti-tumor $CD8^+$ CTL was demonstrated (Ossendorp, F., et al. 1998. J. Exp. Med. 187:693-702). In humans, evidence for a role of $CD4^+$ T cells in anti-tumor immunity comes from the study of tumor infiltrating lymphocytes, which revealed the presence of both $CD8^+$ and $CD4^+$ T cells at the tumor site (Goedegebuure, P.S., et al. 1995. Immunol. Res. 14:119-131; Maccalli, C., et al. 1994. Int. J. Cancer 57:56-62), and from the detection in the sera of neoplastic patients of antibodies directed against tumor antigens (Sahin U. et al., 1997, Curr. Opin. Immunol. 9:709-716). However, in recent years research on the T cell immunity against human tumors has

focused mainly on identification of $CD8^+$ HLA class I restricted CTL responses. For example, WO 95/19783 discloses MAGE-3 derived peptides capable of binding to MHC class I molecules, such as the allele HLA-A1. Such peptides usually have a number of residues ranging from 8 to 10 amino acids.

To date tyrosinase, a tissue-specific antigen expressed in normal and neoplastic cells of melanocytic lineage (Topalian, S.L., et al. 1994. Proc. Natl. Acad. Sci. USA 91:9461-9465.; Yee, C., et al. 1996. J. Immunol. 157:4079-4086), is the only melanoma associated antigen demonstrated as a specific target for $CD4^+$ melanoma reactive T cells and for which $CD4^+$ T cell epitopes have been identified (Topalian, S.L., et al. 1996. J. Exp. Med. 183:1965-1971). WO 97/11669 (Topalian et al.) reports that peptides from this antigen are recognized in association with MHC class II molecules.

Characterization of the $CD4^+$ T cell epitope repertoire on other tumor associated antigens, expecially those that are tumor-specific and shared among tumors of several histotypes (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693), would contribute decisively to improve the efficacy of peptide-based immunization protocols in neoplastic patients.

The family of MAGE genes ("Melanoma Associated Antigen") consists of about 12 members which are expressed in various types of tumors. MAGE-3 is a tumor-specific antigen encoded by a gene expressed in a high proportion of melanomas and in several other tumor histotypes (head and neck squamous cell carcinomas, bladder carcinomas, lung carcinomas and sarcomas) and not in normal tissues, with the exception of testis and placenta (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693). $CD8^+$ CTL from melanoma patients recognize HLA class I restricted MAGE-3

epitopes (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693), and clinical trials with synthetic peptides corresponding to HLA-A1 and/or -A2 MAGE-3 binding sequences are ongoing in patients affected by melanoma and other neoplastic diseases (Van den Eynde, B.J., et al. 1997. Immunol. Today 9:684-693).

According to a first aspect, the invention relates to MAGE-3 derived immunogenic peptides capable of binding to MHC class II molecules. Such peptides have length from 12 to 15 residues and correspond to MAGE-3 fragments (according to the amino acid sequence reported in Gaugler B. et al. 1994, J. Exp. Med. 179, 921-930) 21-35, 111-125, 161-175, 251-265, 286-300, preferably 141-155, 146-160, 156-170, more preferably 171-185, 191-205 and 281-295. The corresponding amino acid sequences are reported in SEQ ID No. 1-11.

The peptides of the invention are characterized by promiscuous binding to different alleles of MHC class II molecules, such characteristic being advantageous in that one same peptide can be recognized by a wider patient population.

In an <u>in vitro</u> binding assay, the peptides of the invention proved capable of binding different purified molecules belonging to widespread HLA-DR alleles, and of inducing activation of $CD4^+$ cells. More particularly, it has been observed that stimulation with the peptides of the invention induces a remarkable proliferation of $CD4^+$ T cells and of their cytolytic activity. CD4+ T cells exposed to such peptides were able to cause lysis of melanoma cells expressing the MAGE-3 protein and the HLA-DR molecules. Details of such experimental evidence are reported in the examples.

The peptides are preferably prepared synthetically, for example according to the procedures described in

Merrifield, (1986) Science 232:341-347, and Barany and Merrifield, The Peptides, Gross and Meienhofer, eds (N.Y., Academic Press), pp. 1-284 (1979). The synthesis can be carried out in solution or in solid phase or with an automatized synthesizer (Stewart and Young, Solid Phase Peptide Synthesis, 2nd ed., Rockford Ill., Pierce Chemical Co. (1984). Alternatively, the recombinant DNA technology can be used, or the peptides can be prepared starting from the natural protein by fragmentation or enzymatic digestion. Furthermore, the amino acid residues can be replaced, preferably conservatively, by other residues of L- or D- amino acids, or added to the disclosed peptides, or they can be chemically modified, for example by amidation of the terminal carboxylic group or by binding with lipophilic groups (e.g. myristyl), or by glycosylation or conjugations with other peptides, to obtain more favourable properties, such as higher affinity to the MHC molecule, higher immunogenicity, better selectivity in inducing the immune response or higher bioavailability after administration. The peptides of the invention can also be chemically derivatized at the side chains which are therefore modified. For example, free carboxylic groups can be derivatized to form salts, methyl- and ethyl- esters or other types of esters or hydrazides.

The peptides of the invention can also be conjugated with known epitopes, for example with epitopes binding HLA molecules of class I, in order to induce a more complete spectrum of responses, of both the cytotoxic and helper type, and to enhance the response against the tumour.

The provision of new epitopes from an antigen not significantly expressed in normal tissues, such as MAGE-3, would allow to prepare vaccines for use in immunotherapy of patients with tumors expressing the same antigen. Furthermore, the $CD4^+$ T cells response induced by the

epitopes is strenghtened in that those cells, in addition to an intrinsic cytotoxic activity, exhibit also helper activity through the stimulation and proliferation of other T cells, such as $CD8^+$T cells, as well as through macrophages activation.

Therefore, according to a further aspect, the invention provides pharmaceutical compositions containing an effective amount of a peptide of the invention, optionally in combination with other known peptides binding MHC class I molecules and corresponding to $CD8^+$ T cell epitopes, such as the peptides described in WO95/19783. In addition to the active ingredients , the compositions will contain pharmaceutically acceptable excipients. "Effective amount" herein means a sufficient amount to activate specific lymphocytes and induce an effective response against the tumor. Such an amount will depend on the peptide used, the administration, the severity of the disease to be treated and the general conditions of the patient and will usually range from 1 to 50 μg/ml, for example in case of peptides being loaded on dendritic cells.

According to a preferred embodiment, such compositions will be used for the preventive vaccination of patients with predisposition to neoplasias or in the therapeutical vaccination of neoplastic patients. "Vaccination" herein means both active immunization, i.e. the in vivo administration of the peptides to elicit an in vivo immune response directly in the patient, as in conventional vaccination protocols, for example against pathogens, and passive immunization, i.e. the use of the peptides to activate in vitro anti-tumor $CD4^+$ cells, which are subsequently re-inoculated into the patient.

The techniques for the preparation and the use of vaccines are known to those skilled in the art and are

described, per example, in Paul, Fundamental Immunology, Raven Press, New York (1989) or Cryz, S. J., Immunotherapy and Vaccines, VCH Verlagsgesselschaft (1991). Vaccines are conventionally prepared in the form of injectables, suspensions or solutions, but they can also be used in the form of solid preparations or liposomes. The immunogenic ingredients can be mixed with pharmacologically acceptable excipients, such as emulsifiers, buffering agents and adjuvants which increase the efficacy of the vaccine. The latter can be administered according to single or multiple dosage schedule. Multiple dose provides 1 to 10 separate doses, each containing a quantity of antigen varying from 1 μg to 1000 μg, followed by further doses at subsequent time intervals, necessary to maintain or to reinforce the immune response and, if required by the subject, a further dose after several months. In any case, the treatment regimen will depend on the response elicited in the treated patient, general conditions and progress of the tumor.

In a further aspect, the invention provides a method for inducing an immune response against tumor cells expressing a MAGE-3 antigen which comprises incubating APC cells (Antigen Presenting Cells) with the peptides of the invention in conditions suitable for the activation of effectors T $CD4^+$.

Such conditions comprise loading autologous APC with the peptides and the subsequent exposure to purified T $CD4^+$lymphocites . Suitable APC cells are autologous peripheral blood mononuclear cells (PBMC), dendritic cells, macrophages or activated B cells. The peptides are added to an APC culture for a sufficient time to obtain the peptide/APC binding, and subsequently a cell population containing $CD4^+$ CTLs is added, thereby causing activation and proliferation of CTLs. According to a preferred embodiment, T cells are taken from the treated patient and

optionally purified, then, after activation as described above and expansion in suitable culture medium, they are reintroduced in the same patient. Culture media can contain one or more cytokines (such as IL-2 or T-cell Growth Factor) which contribute to the expansion of $CD4^+$ precursors.

In a preferred embodiment, cells playing an important role in the induction of the immune response, such as APC, dendritic cells etc., are genetically engineered with vectors encoding the peptides of the invention (for example viral or retroviral vectors, such as those from adenovirus or lentivirus or MLV). Furthermore, the peptides can also be fused with a suitable protein carrier, to have a satisfactory processing and expression at the cell surface. Accordingly, the DNA encoding for the epitopes of the invention, may be inserted in a suitable expression vector, under the control of a suitable viral promoter, such as CMV or SV40, when a very efficient expression is required, or an inducible promoter such as that controlled by ecdysone. The epitopes herein referred correspond to the nucleotide fragments listed in the following Table 1, according to the (human) MAGE-3 gene sequence deposited at GenBank under the accession number U03735:

TABLE 1

| aa | Amino acid sequence | Nt |
|---|---|---|
| 21-35 | EALGLVGAQAPATEE | 2525-2569 |
| 111-125 | RKVAELVHFLLLKYR | 2795-2839 |
| 141-155 | GNWQYFFPVIFSKAS | 2885-2929 |
| 146-160 | FFPVIFSKASSSLQL | 2900-2944 |
| 156-170 | SSLQLVFGIELMEVD | 2930-2974 |
| 161-175 | VFGIELMEVDPIGHL | 2945-2989 |
| 171-185 | PIGHLYIFATCLGLS | 2975-3019 |
| 191-205 | GDNQIMPKAGLLIIV | 3035-3079 |
| 251-265 | VQENYLEYRQPVGSD | 3215-3259 |
| 281-295 | TSYVKVLHHMVKISG | 3305-3349 |
| 286-300 | VLHHMVKISGGPHIS | 3320-3364 |

The invention also relates to antibodies, fragments or derivatives thereof, directed to the above described peptides. The general methodology for producing antibodies is well known and is disclosed per example in Kohler and Milstein, 1975, Nature 256, 494 or in J.G.R. Hurrel, Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press Inc., Boco Raron, FL (1982). The antibodies can be polyclonal or, preferably, monoclonal, or antibody fragments like be F(ab')2, Fab, Fv or scFv.

Still a further aspect of the invention is a method for monitoring the frequency and the expansion of specific precursors for the peptides or the complete MAGE-3 protein, in neoplastic patients subject to active vaccination, by the ELISPOT technique (Herr, W. Et al., 1997, J. Immunol. Methods 203:141-52) or by cytofluorimetric analysis using tetramers consisting of tetrameric soluble molecules avidin-biotin-MHC class II, pulsed with the relevant peptide (Yee, C. et al. 1999, J. Immunol. 162:2227-2234).

Description of the Figures

Fig. 1: Proliferative activity of $CD4^+$ T cells challenged with the MAGE-3 Pool, tested in 2-d microproliferation assays.

The data are representative of (n=x) experiments, and are means of triplicate determinations $\pm$ SD. Panel A (n=6): responses to MAGE-3 Pool (0.01, 0.5, 0.1, 0.5, 1 and 5 μg/ml). Panel B (n=3): responses to recombinant MAGE-3 protein (5, 10 and 20 μg/ml). Panel C (n=7): responses to the individual synthetic peptides forming the MAGE-3 Pool (10 μg/ml) at different weeks of propagation. The blank (i.e. the basal level of proliferation of $CD4^+$ T cells in the presence of APC only) was subtracted and was as follows: 2 weeks: $30,866\pm1,115$; 4 weeks: $7,106\pm2,201$; and 6 weeks: $21,838\pm2,767$. Asterisks indicate responses significantly higher than the blanks (*, $P<0.001$ and ** $P<0.025$, as determined by unpaired, one-tailed Student's *t* test). Panel D (n=5): response to MAGE-3 Pool (5 μg/ml) (a) and to peptide corresponding to sequence 281-295 (b), in the presence of different doses of L243 mAb (0.25 and 0.5 μg/ml). The blank was $1,251\pm444$, the proliferation of $CD4^+$ T cells in the presence of MAGE-3 pool was $28,191\pm373$, and the proliferation in the presence of sequence 281-295 was $22,504\pm141$.

Fig. 2: Cytolytic activity of MAGE-3 specific $CD4^+$ T cells.

The data are representative of (n=x) experiments, and are means of triplicate determinations$\pm$SD. Panel A (n=6): lytic activity against different HLA-DR matched and unmatched melanoma cells. HLA-DR types of $CD4^+$ T cells and melanomas are indicated at the bottom along with their symbols.

Fig. 3: $CD4^\pm$ T cells recognize MAGE-3 (281-295) in association with HLA-DR11 on OI TC cells.

The data are representative of (n=x) experiments, and

are means of triplicate determinations±SD. Panel A (n=3): lytic activity of $CD4^+$ CTL against LCL alone or LCL pulsed with MAGE-$3_{141-154}$, MAGE-$3_{146-160}$ and MAGE-$3_{281-295}$. Panel B (n=3): cold target inhibition experiments. Cold targets [OI TC (circles) and LCL pulsed with MAGE-$3_{281-295}$ (squares)] were used to inhibit the lytic activity of MAGE-3 specific $CD4^+$ CTL against hot OI TC (E/T ratio was 40:1). Percentage of specific lysis against OI TC cells in the absence of cold targets was 26±1.2%.

For the abbreviations of HLA phenotypes and of cell lines see Example 4.

The following examples illustrate the invention in greater detail.

**EXAMPLES**

Example 1

DR-Peptide binding assay.

Peptide interactions with detergent-solubilized DR molecules were measured using an ELISA-based high-flux competition assay (Radrizzani, L., et al. 1997. J. Immunol. 159:703-711). HLA-DR molecules were isolated from the following human lymphoblastoid cell lines (LCL): DR1 (DRB1*0101) from HOM-2, DR3 (DRB1*0301) from WT49, DR4 (DRB1*0401) from PREISS, DR5 (DRB1*1101) from SWEIG, DR7 (DRB1*0701) from EKR, and DR8 (DRB1*0801) from BM9. DR2 (DRB1*1501) was isolated from the L cell transfectant L466.1. The molecules were affinity purified using the mAb 1-1C4 (Cammarota, G., et al. 1992. Nature 356:799-801), as described in (Sinigaglia, F., et al. 1992. Methods Enzymol. 203:370-386). Peptide competition assay was conducted to measure the ability of unlabeled peptides to compete with a biotinylated indicator peptide for binding to purified DR molecules. The following biotinylated indicator peptides were used: $GFKA_7$ for DR1 and DR7; $GIRA_2YA_4$ for DR2; $LAYDA_5$ for DR3; UD4 for DR4 (Hammer, J., et al. 1995. J. Exp. Med.

181:1847-1855); TT 830-843 for DR5; and $GYRA_6L$ for DR8. The biotinylated indicator peptide and HLA-DR molecules were incubated with 10-fold dilutions (0.001-100 mM) of the unlabeled competitor peptides (peptides corresponding to the MAGE-3 predicted sequences). To determine peptide binding affinity, the promiscuous $HA_{307-319}$ peptide from influenza hemagglutinin (Roche, P.A., et al. 1990. J. Immunol. 144:1849-1856) was included in each competition assay. The relative binding data of the unlabeled competitor peptides were expressed as inhibitory concentration ($IC_{50}$): i.e. the concentration of competitor peptide required to inhibit 50% of binding of the biotinylated indicator peptide.

The results of the binding assay are reported in the following Table 2.

Table 2: Determination of HLA-DR binding by MAGE-3 derived peptides

HLA-DR alleles

| Residues | Sequence | *0101 | *0301 | *0401 | *0701 | *0801 | *1101 | *1501 |
|---|---|---|---|---|---|---|---|---|
| 141-155 | GNWQYFFPVIFSKAS | 25 | >100(A) | 7 | 0.1 | 3.2 | 0.6 | 3 |
| 146-160 | FFPVIFSKASSSLQL | 10 | 7 | 2 | 0.01 | 1.5 | 1.8 | 0.2 |
| 156-170 | SSLQLVFGIELMEVD | 7 | 90 | 45 | 0.03 | 7 | 28 | 0.18 |
| 171-185 | PIGHLYIFATCLGLS | 0.3 | 2.8 | 0.9 | 0.01 | 1.5 | 0.9 | 0.03 |
| 281-295 | TSYVKVLHHMVKISG | 15 | 26 | 70 | 0.02 | 0.01 | 0.03 | 0.5 |
| 21-35 | EALGLVGAQAPATEE | 14 | >100 | >100 | 25 | >100 | >100 | 22 |
| 111-125 | RKVAELVHFLLLKYR | >100 | >100 | >100 | 55 | 7 | 0.7 | 0.055 |
| 161-175 | VFGIELMEVDPIGHL | >100 | 0.6 | 28 | 10 | 100 | >100 | 100 |
| 191-205 | GDNQIMPKAGLLIIV | >100 | >100 | >100 | 6 | 1 | 4 | 0.07 |
| 251-265 | VQENYLEYRQVPGSD | >100 | >100 | >100 | 26 | 10 | 60 | 5 |
| 286-300 | VLHHMVKISGGPHIS | 15 | >100 | >100 | 0.01 | 14 | 0.2 | 0.48 |

The binding data are expressed as relative binding capability ($IC_{50}$ $\mu$M), calculated as concentration of competitor peptide required to inhibit 50% of binding of the biotinylated indicator peptide (indicator peptide). (a) $IC_{50}$ values higher than 100 $\mu$M are outside the sensitivity limits of the binding assay.

Example 2

Peptide synthesis.

Peptides were synthetized on a 9050 Millipore synthesizer (Millipore Volketswil, Switzerland). The purity of the peptides was evaluated by RP-HPLC and electron spray mass spectrometry. Synthetic peptides were lyophilized and then reconstituted in DMSO at 2 mg/ml concentration and diluted in PBS as needed.

Example 3

Propagation of $CD4^{\pm}$ T cells and proliferation assay.

The synthetic peptides corresponding to the MAGE-3 sequences most promiscuous (141, 155, 146-160, 156-170, 171-185, 281-295) for HLA-DR binding (see Tables 1 and 2) were pooled (MAGE-3 Pool) and used to stimulate the PBMC of an healthy donor whose HLA type, identified by standard serologic typing, is: A1, A2/B41, B52/DR11, as described in Protti, M.P., et al. 1990. J. Immunol. 144:1711-1720. Briefly, $20x10^6$ PBMC were cultivated for 7 days in RPMI 1460 (GIBCO, Grand Island, NY) supplemented with 10% heat inactivated human serum (Technogenetics, Milan, Italy), 2mM l-glutamine, 100 U/ml penicillin, 50 μg/ml streptomycin (Biowhittaker, Walkersville, MD) (TCM) containing the MAGE-3 Pool (1 μg/ml of each peptide). The reactive lymphoblasts were isolated on a Percoll gradient (Protti, M.P., et al. 1990. J. Immunol. 144:1711-1720), further expanded in T cell growth factor (Lymphocult, Biotest Diagnostic Inc., Dreieich, West Germany) and restimulated at weekly intervals with the same amount of antigen plus irradiated (4000 rad) autologous PBMC as APC.

In the proliferation assay $CD4^+$ T cells and autologous irradiated PBMC were diluted in TCM to

$2x10^5$/ml and $2x10^6$/ml, respectively and plated in triplicate in 96 round-bottom well plates (100 µl of $CD4^+$ T cells and 100 µl of APC). The cells were stimulated with different concentrations of MAGE-3 pool (0.05, 0.1, 0.5, 1 and 5 µg/ml), each peptide (10 µg/ml) and different concentrations of rMAGE-3 protein (5, 10 and 20 µg/ml). Triplicate wells with $CD4^+$ T cells alone and APC alone were used as controls. Three wells with $CD4^+$ T cells plus APC did not receive any stimulus to determine the basal growth rate (blank). In inhibition experiments different concentrations of mAb L243 or an isotype matched irrelevant mAb (0.25 and 0.5 µg/ml) were added in triplicate wells of $CD4^+$ cells plus APC stimulated with MAGE-3 pool (5 µg/ml) or MAGE-$3_{281-295}$ (10 µg/ml). After three days the cultures were pulsed for 16 h with [$^3$H]TdR (1 mCi, well, 6.7 Ci/mol, Amersham Corp., Milan, Italy). The cells were collected with a Skatron Titertek multiple harvester (Skatron Inc., Sterling, VA) and the thymidine incorporated was measured in a liquid scintillation counter.

T cells were 94% $CD4^+$ after 1 week of culture and could be propagated in long term culture by weekly restimulation with the MAGE-3 Pool in the presence of autologous irradiated PBMC. In microproliferation assays (Fig. 1) the cells responded vigorously to the MAGE-3 Pool (Panel A), even at low concentrations (100-500 ng/ml). Reactivity to the individual peptides forming the pool was also periodically investigated (Panel C): the $CD4^+$ T cells predominantly recognized the peptide corresponding to MAGE-$3_{281-295}$ and, although to a much lower extent, the peptides corresponding to the overlapping sequences MAGE-$3_{141-154}$ and MAGE-$3_{146-160}$.

Reactivity to MAGE-$3_{281-295}$ increased during the propagation of the line (Panel C). The proliferative activity of $CD4^+$ T cells in the presence of MAGE-3 Pool (Panel Da) or MAGE-$3_{281-295}$ (Panel Db) was inhibited by addition in culture of different concentrations of L243 mAb (Panel D), demonstrating that the recognition of MAGE-3 sequences was HLA-DR restricted.

The HLA-DR11+ PBMC from the healthy donor were also stimulated with a second pool of synthetic peptides corresponding to the MAGE-3 sequences 21-35, 111-125, 161-175, 191-205, 251-265 and 286-300. The $CD4^+$ T cells proliferated in a dose dependent manner to different concentrations of the MAGE-3 pool II, and the study of the epitope repertoire of the MAGE-3 specific $CD4^+$ T cells showed recognition of sequences MAGE-$3_{111-125}$, MAGE-$3_{161-175}$ and predominantly MAGE-$3_{191-205}$. Furthermore, MAGE-3 specific $CD4^+$ T cells from a melanoma patient, whose HLA-DR type is HLA-DR4/DR11, recognized the sequences MAGE-$3_{141-155}$, MAGE-$3_{146-160}$, MAGE-$3_{156-170}$, MAGE-$3_{171-185}$ and MAGE-$3_{281-295}$. The study of the restriction element showed that all sequences were recognized in association with the HLA-DR4 allele, demonstrating that sequences 141-155, 146-160 and 281-295 are presented to $CD4^+$ T cells in association at least with two different alleles (HLA-DR11 and HLA-DR 4).

Example 4

Cytotoxicity assay

$CD4^+$ T cells were tested for specific lytic activity in a standard 4-h $^{51}Cr$ release assay as described in Protti, M.P., et al. 1996. Cancer Res. 56:1210-1213. The following targets were used: melanoma

cells (SK-Mel 28, HT144, OI TC described in Imro, M.A., et al. 1998. Hum. Gene Ther. 9:1335-1344 and MD TC established in our laboratory from a cutaneous metastasis), and LCL. The HLA-DR type of target cells, identified by molecular or serologic typing, was: SK-Mel 28 (DR*04*13), HT144 (DR*04*07), OI TC (DR*01*11), MD TC (DR*04*11), LCL (DR11). In cold target competition assays, unlabeled target cells (cold targets) were seeded in plates at serial ratios of hot-to-cold target cells. Effector $CD4^+$ T cells and $^{51}Cr$-labeled target cells (hot targets) were then added, and cytotoxicity assessed as described above. Percentage inhibition was calculated as follows:

[(% specific lysis without cold target-% specific lysis with cold target)/(% specific lysis without cold target)]x100.

$CD4^+$ T cells showed cytolytic activity against OI TC and MD TC which express the HLA-DR11 restricting allele, while they did not kill SK-Mel 28 and HT144 which express unrelated HLA-DR alleles (Figure 2a). To verify whether the cytolytic $CD4^+$ T cells recognized HLA-DR11 restricted MAGE-3 epitopes on melanoma cells, first was tested their lytic activity against HLA-$DR11^+$ LCL unpulsed, or pulsed with the synthetic peptides recognized in microproliferation assays. LCL pulsed with MAGE-$3_{281-295}$ were strongly recognized by the $CD4^+$ T cells, while no killing activity against LCL unpulsed or pulsed with MAGE-$3_{141-154}$ and MAGE-$3_{146-160}$ was detectable (Figure 3a). Subsequently, cold target inhibition experiments were performed which showed that the lytic activity of $CD4^+$ T cells against OI TC was inhibited by the addition of LCL pulsed with MAGE-$3_{281-}$

295 (Figure 3b), demonstrating that this sequence is indeed presented by HLA-DR11 on the OI TC melanoma cells. These results further demonstrate that MAGE-$3_{281-295}$ is naturally processed and forms a cytotoxic $CD4^+$ T cell epitope.

$CD4^+$ T cells specific for sequence MAGE-$3_{191-205}$ also showed cytolytic activity against MAGE-3/HLA-DR11+ melanoma cells and cold/target inhibition experiments showed that the sequence 191-205 was indeed recognized at the surface of the melanoma cells in association with the HLA-DR11 allele and therefore this epitope is naturally processed.

In the case of the patient, the $CD4^+$ T cells showed cytolytic activity against the autologous tumor that expresses the MAGE-3 antigen, and against the SK-Mel 28 melanoma cells that express the antigen and the HLA-DR4 retriction allele, while they did not kill melanoma cells expressing the MAGE-3 protein but an unrelated HLA-DR allele.

CLAIMS

1. Peptides binding MHC class II molecules selected from the group consisting of:

a) EALGLVGAQAPATEE
b) RKVAELVHFLLLKYR
c) GNWQYFFPVIFSKAS
d) FFPVIFSKASSSLQL
e) SSLQLVFGIELMEVD
f) VGFIELMEVDPIGHL
g) PIGHLYIFATCLGLS
h) GDNQIMPKAGLLIIV
i) VQENYLEYRQVPGSD
j) TSYVKVLHHMVKISG
k) VLHHMVKISGGPHIS

2. Monoclonal or polyclonal antibodies directed to peptides of claim 1.

3. A pharmaceutical composition comprising an effective amount of a peptide of claim 1 together with pharmaceutically acceptable excipients.

4. A composition as claimed in claim 3, further comprising one or more peptides binding MHC class I molecules corresponding to CTL $CD8^+$ epitopes.

5. A composition as claimed in claims 3 and 4, for use as a vaccine.

6. A method for inducing an immune response against tumor cells expressing a MAGE-3 antigen, which method comprises contacting APC cells with the peptides of claim 1 in suitable conditions for the activation of effector $CD4^+$ T cells.

7. A method as claimed in claim 6, wherein autologous APC are loaded with the peptides and subsequently

contacted with purified $CD4^+$ lymphocytes.

8. The use of the peptides of claim 1 for the preparation of an anti-tumor medicament.

9. The use as claimed in claim 8, wherein said medicament is a vaccine.

FIG. 1


A
B
C
D
cpm x 10-3
Pool MAGE-3 (ug/ml)
rMAGE-3 (ug/ml)
Sequences : MAGE-3
281-295
171-185
156-170
146-160
141-154
2 Weeks
4 Weeks
6 Weeks
cpm x 10-3
% Inhibition
a
b
0.25
0.5
L243 (ug/ml)

FIG. 2


A
30
20
10
0
% Lysis
1
10
100
E/T
CD4
DR11
MD TC
DR*04*11
01 TC
DR*01*11
SK-Mel 28
DR*04*13
HT144
DR*04*07

FIG. 3


A
80
60
40
20
0
1
1
10
100
E/T
LCL+281-295
LCL+146-160
LCL+141-154
LCL
B
100
80
60
40
20
0
1
10
100
1000
01 TC
LCL+281-295

SEQUENCE LISTING

<110> FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR

<120> MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF CLASS II AND THE USE THEREOF

<130> SAN RAFFAELE

<140>
<141>

<160> 11

<170> PatentIn Ver. 2.1

<210> 1
<211> 15
<212> PRT
<213> HUMAN

<400> 1
Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala Thr Glu Glu
1 5 10 15

<210> 2
<211> 15
<212> PRT
<213> HUMAN

<400> 2
Arg Lys Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg
1 5 10 15

<210> 3
<211> 15
<212> PRT
<213> HUMAN

<400> 3
Gly Asn Trp Gln Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser
1 5 10 15

<210> 4
<211> 15
<212> PRT
<213> HUMAN

<400> 4
Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
1 5 10 15

<210> 5
<211> 15
<212> PRT
<213> HUMAN

<400> 5
Ser Ser Leu Gln Leu Val Phe Gly Ile Glu Leu Met Glu Val Asp
1 5 10 15

<210> 6
<211> 15
<212> PRT
<213> HUMAN

<400> 6
Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu
1 5 10 15

<210> 7
<211> 15
<212> PRT
<213> HUMAN

<400> 7
Pro Ile Gly His Leu Tyr Ile Phe Ala Thr Cys Leu Gly Leu Ser
1 5 10 15

<210> 8
<211> 15
<212> PRT

<213> HUMAN

<400> 8
Gly Asp Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val
1 5 10 15

<210> 9
<211> 15
<212> PRT
<213> HUMAN

<400> 9
Val Gln Glu Asn Tyr Leu Glu Tyr Arg Gln Pro Val Gly Ser Asp
1 5 10 15

<210> 10
<211> 15
<212> PRT
<213> HUMAN

<400> 10
Thr Ser Tyr Val Lys Val Leu His His Met Val Lys Ile Ser Gly
1 5 10 15

<210> 11
<211> 15
<212> PRT
<213> HUMAN

<400> 11
Val Leu His His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser
1 5 10 15

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52045 A3

(51) International Patent Classification[7]: C07K 14/47, A61K 38/17, A61P 35/00

(21) International Application Number: PCT/EP00/01458

(22) International Filing Date: 23 February 2000 (23.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI99A000396 26 February 1999 (26.02.1999) IT

(71) Applicant *(for all designated States except US)*: **FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR** [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PROTTI, Maria, Pia** [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT). **DELLABONA, Paolo** [IT/IT]; Via Olgettina, 60, I-20132 Milano (IT).

(74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States *(national)*: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *With international search report.*

(88) Date of publication of the international search report:
4 January 2001

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 00/52045 A3

(54) Title: MAGE-3 DERIVED IMMUNOGENIC PEPTIDES PRESENTED BY MHC OF CLASS II AND THE USE THEREOF

(57) Abstract: Peptides derived from the protein MAGE-3, pharmaceutical compositions containing them and the use thereof for inducing an immune response against tumors.

# INTERNATIONAL SEARCH REPORT

Inter[illegible]l Application No
PCT/EP 00/01458

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K14/47 A61K38/17 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, STRAND, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| P,X | WO 99 14326 A (STROOBANT VINCENT ;HEIRMAN CARLO (BE); CHAUX PASCAL (BE); CORTHALS) 25 March 1999 (1999-03-25) see Seq ID's 3-12 claims; examples | 1-3,6-9 |
| P,X | CHAUX P ET AL: "IDENTIFICATION OF MAGE-3 EPITOPES PRESENTED BY HLA-DR MOLECULES TO CD4+ T LYMPHOCYTES" JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO1, vol. 189, no. 5, 1 March 1999 (1999-03-01), pages 767-777, XP000857617 ISSN: 0022-1007 page 774, left-hand column, paragraph 4 -page 775, right-hand column, paragraph 1 | 1 |

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 11 September 2000 | 18/09/2000 |

| Name and mailing address of the ISA | Authorized officer |
|---|---|
| European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | Fuhr, C |

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication,where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| P,A | WO 99 45954 A (EPIMMUNE INC)<br>16 September 1999 (1999-09-16)<br>claims; examples | 1,2,4,5,<br>8,9 |
| A | WO 99 03972 A (AKIYOSHI TSUYOSHI ;YASUMOTO MASAZUMI (JP); IDENO MITSUKO (JP); FUJ)<br>28 January 1999 (1999-01-28)<br>see sequence listing<br>abstract | 1,2,4,5,<br>8,9 |
| A | WO 95 19783 A (CELIS ESTEBAN ;GREY HOWARD M (US); CYTEL CORP (US); KUBO RALPH T ()<br>27 July 1995 (1995-07-27)<br>claims; examples | 1,2,4,5,<br>8,9 |
| A | WO 98 33888 A (EPIMMUNE INC)<br>6 August 1998 (1998-08-06)<br>claims; examples | 1,2,4,5,<br>8,9 |
| A | WO 94 20127 A (CYTEL CORP)<br>15 September 1994 (1994-09-15)<br>claims; examples | 1,2,4,5,<br>8,9 |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 00/01458

| Patent document cited in search report | Publication dat | Patent family member(s) | Publication date |
|---|---|---|---|
| WO 9914326 A | 25-03-1999 | US 5965535 A | 12-10-1999 |
| | | AU 9306198 A | 05-04-1999 |
| | | EP 1012283 A | 28-06-2000 |
| | | ZA 9808124 A | 05-03-1999 |
| WO 9945954 A | 16-09-1999 | AU 6465598 A | 27-09-1999 |
| WO 9903972 A | 28-01-1999 | NONE | |
| WO 9519783 A | 27-07-1995 | US 5662907 A | 02-09-1997 |
| | | AU 1834095 A | 08-08-1995 |
| | | AU 4111999 A | 23-09-1999 |
| | | CA 2181920 A | 27-07-1995 |
| | | EP 0749315 A | 27-12-1996 |
| | | SG 49743 A | 15-06-1998 |
| WO 9833888 A | 06-08-1998 | AU 6140998 A | 25-08-1998 |
| | | EP 1012238 A | 28-06-2000 |
| WO 9420127 A | 15-09-1994 | AU 6359494 A | 26-09-1994 |
| | | AU 6597998 A | 02-07-1998 |
| | | BR 9406652 A | 10-09-1996 |
| | | CA 2157510 A | 15-09-1994 |
| | | CN 1118572 A | 13-03-1996 |
| | | EP 0703783 A | 03-04-1996 |
| | | JP 8507525 T | 13-08-1996 |
| | | NZ 263050 A | 24-11-1997 |
| | | SG 49008 A | 18-05-1998 |